SPRAVATO® (esketamine) approved in the U.S. as the first and …
3 days ago · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental …
SPRAVATO® (esketamine) approved in the U.S. as the first and …
3 days ago · Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for …
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
2 days ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe …
FDA approves first-of-its-kind nasal spray for severe depression
Spravato is now cleared to use by itself after years of clinical trials. By Andrew Paul Posted 24 Hours Ago Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, …
Johnson & Johnson ketamine-derived nasal spray gets FDA …
1 day ago · Johnson & Johnson beat analyst expectations for revenue by $70 million, but highlighted possible negative impacts in its outlook from an ongoing talc lawsuit and slower …
FDA Approves Spravato Nasal Spray for Treatment-Resistant …
2 days ago · Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and …
FDA allows standalone use of nasal spray antidepressant Spravato ...
2 days ago · In the first nine months of 2024, the drug generated sales of about $780 million for its maker, Johnson & Johnson. Spravato is intended to be administered under the direct …
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine…
Titusville, New Jersey, July 22, 2024 – Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug …
FDA Approves Johnson & Johnson's Spravato as Standalone …
2 days ago · The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant …
FDA Approves Esketamine as First Monotherapy for Treatment …
3 days ago · The US Food and Drug Administration (FDA) approved esketamine (SPRAVATO) CIII nasal spray as the first monotherapy for adults with treatment-resistant depression (TRD), …
- Some results have been removed